Journal
PEDIATRIC BLOOD & CANCER
Volume 57, Issue 2, Pages 321-323Publisher
WILEY PERIODICALS, INC
DOI: 10.1002/pbc.23098
Keywords
angiogenesis; molecular biology and oncogenes; new agents; vascular malformations
Categories
Ask authors/readers for more resources
Bannayan-Riley-Ruvacalba syndrome (BRRS) belongs to the PTEN hamartoma tumor syndromes and is characterized by a high risk of malignancy in early adulthood added to local destructive effects of hamartomas in childhood. There is no standard treatment for this condition and patients are usually offered symptomatic surgical relief. Rapamycin has been reported to be effective in the management of other conditions associated with PTEN mutation. We report here a case of BRRS in a 6-year-old male with progressive loss of function of left hand and forearm associated with pain. He was treated with oral rapamycin and regained pain-free full mobility. Pediatr Blood Cancer 2011;57:321-323. (C) 2011 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available